Deep Dive Investor Report | March 11, 2026
Horizon Therapeutics plc, founded in 2005 and headquartered at 70 St. Stephen's Green, Dublin 2, Ireland, operated as an independent global biotechnology company focused on rare, autoimmune, and severe inflammatory diseases until its acquisition by Amgen Inc. on October 6, 2023, for $27.8 billion ($116.50 per share in cash). At the time of acquisition, Horizon employed over 2,000 people worldwide across nine offices. The company is now fully integrated as a subsidiary of Amgen, with its product portfolio forming the cornerstone of Amgen's rare disease business unit.
Horizon's product portfolio generated substantial revenue for Amgen in 2024 and 2025:
Combined Horizon Portfolio Revenue: Approximately $4.2-4.5 billion in 2024, representing 12-13% of Amgen's total revenue of $33.4 billion (19% YoY growth).
The Horizon acquisition represents Amgen's largest deal in company history, surpassing its 2001 Immunex buyout. The portfolio strengthens Amgen's position in inflammation and rare disease markets, with CEO Robert Bradway noting it advances core strategy and delivers revenue growth plus non-GAAP EPS accretion from 2024 onward. The rare disease franchise, anchored by Horizon products, achieved $4.5 billion in sales in 2024, positioning Amgen as a major player in high-value orphan drug markets.
Horizon Therapeutics plc was founded in 2005 as an Irish public limited company (registered number 507678), establishing its global headquarters in Dublin, Ireland. The company went public in 2011 with two marketed products, beginning its transformation into an innovation-driven biotechnology company.
| Year | Acquisition | Value | Key Assets |
|---|---|---|---|
| 2014 | Vidara Therapeutics | N/A | Reincorporation as Horizon Pharma plc in Ireland |
| 2015 | Hyperion Therapeutics | $1.1B | Orphan disease drug portfolio expansion |
| 2015 | Crealta Holdings | $510M | Rare disease products |
| 2016 | Raptor Pharmaceutical | $800M | PROCYSBI, QUINSAIR |
| 2017 | River Vision Development | $145M | Teprotumumab (TEPEZZA) development |
| 2021 | Viela Bio Inc. | $3.0B | UPLIZNA (inebilizumab), pipeline expansion |
Amgen Inc. is the sole parent and owner of Horizon Therapeutics following the October 2023 acquisition. Amgen is a publicly traded company listed on NASDAQ (ticker: AMGN).
As of the most recent filings, Amgen has 3,426 institutional owners holding a total of 468.6 million shares. The largest institutional shareholders include:
Amgen's Board of Directors consists of 12 members elected at the 2025 Annual Meeting:
| Director | Role |
|---|---|
| Robert A. Bradway | Chairman & CEO |
| Robert A. Eckert | Lead Independent Director |
| Wanda M. Austin | Independent Director |
| Michael V. Drake | Independent Director |
| Brian J. Druker, M.D. | Independent Director |
| Greg C. Garland | Independent Director |
| Charles M. Holley Jr. | Independent Director |
| S. Omar Ishrak | Independent Director |
| Tyler Jacks, Ph.D. | Independent Director |
| Mary E. Klotman, M.D. | Independent Director |
| Ellen J. Kullman | Chair, Corporate Responsibility Committee |
| Amy E. Miles | Independent Director |
| Executive | Title | 2024 Compensation |
|---|---|---|
| Robert A. Bradway | Chairman and CEO | $24.4M |
| Peter H. Griffith | Chief Financial Officer | $7.8M |
| Vikram Karnani | EVP, Global Commercial and Medical Affairs, Rare Disease | Not disclosed |
| Murdo Gordon | EVP, Global Commercial Operations | $8.5M |
| David M. Reese, M.D. | EVP, Research & Development (CTO) | $8.1M |
Note on Rare Disease Leadership: Vikram Karnani serves as the primary P&L owner for the Horizon portfolio and Amgen's rare disease franchise. He oversees commercial strategy, market access, and medical affairs for TEPEZZA, KRYSTEXXA, UPLIZNA, and ultra-rare products.
Timothy P. Walbert served as Chairman, President, and CEO of Horizon Therapeutics from 2008 until the October 2023 acquisition. Following the deal, Walbert transitioned to a senior advisor role at Amgen. He has since taken on multiple board positions including Independent Director at Crystalys Therapeutics (appointed February 2026), Director at Odyssey Therapeutics (October 2024), and director roles at Latigo Biotherapeutics, Mirum Pharmaceuticals, Century Therapeutics, Sagimet Biosciences, and Cour Pharmaceuticals.
| Product | Indication | FY 2024 Revenue | Growth | Patent Status |
|---|---|---|---|---|
| TEPEZZA | Thyroid eye disease | $1.9B | +3% (FY25) | No high-certainty patents; minimal near-term biosimilar risk |
| KRYSTEXXA | Chronic refractory gout | $1.2B | +3% (Q3'25) | US patents expire 2030-2036 |
| UPLIZNA | NMOSD, IgG4-RD, gMG (pipeline) | $379M | +14% (Q1'25) | US expires March 2030; EU 2027 (SPC to 2032) |
| RAVICTI | Urea cycle disorders | $758M combined | Stable | Not publicly disclosed |
| PROCYSBI | Cystinosis | |||
| ACTIMMUNE | CGD, osteopetrosis | |||
| BUPHENYL | Urea cycle disorders | |||
| QUINSAIR | Cystic fibrosis |
Based on Amgen earnings calls and leadership statements, the top 5 Horizon products emphasized by CEO Robert Bradway and EVP Vikram Karnani are:
| Program | Indication | Phase | Expected Milestone |
|---|---|---|---|
| TEPEZZA Subcutaneous | Moderate-to-severe active TED | Phase 2b/3 | Interim data 2026-2027 |
| TEPEZZA EU Launch | TED (approved) | Commercial | H2 2025 launch |
| TEPEZZA Japan | TED (approved) | Commercial | Ongoing (approved Sept 2024) |
| KRYSTEXXA + MTX | Chronic refractory gout | Approved | Ongoing adoption |
| UPLIZNA IgG4-RD | IgG4-related disease | Approved | Commercialization (Dec 2025 approval) |
| UPLIZNA gMG | Generalized myasthenia gravis | Regulatory Filing | BLA submission H1 2025 |
| TEPEZZA Chronic TED | Chronic/inactive TED | Phase 3 | TBD |
| Competitor | Mechanism | Status | Threat Level |
|---|---|---|---|
| Linsitinib (Sling) | Oral IGF-1R antagonist | Phase IIb/III positive (Jan 2025) | HIGH |
| Tocilizumab | IL-6 inhibitor (SC) | Phase data; second-line | MODERATE |
| Lonigutamab | SC anti-IGF-1R antibody | Phase 1-2 | LOW-MODERATE |
| Competitor | Mechanism | Status | Threat Level |
|---|---|---|---|
| ABP-671 (lingdolinurad) | Oral URAT1 inhibitor | Phase 2b/3 superiority | HIGH |
| SEL-212 | Monthly pegylated uricase | Top 2025 contender | HIGH |
| Pozdeutinurad (Sobi) | Next-gen oral URAT1 | Pipeline | MODERATE |
| Product | 2024 Revenue | Peak Sales Estimate | Key Drivers |
|---|---|---|---|
| TEPEZZA | $1.9B | $2.5-3B+ | EU/Japan expansion, SC formulation |
| KRYSTEXXA | $1.2B | $1.7B+ | MTX protocol, CKD expansion |
| UPLIZNA | $379M | $600M-1B | IgG4-RD, gMG approvals |
| Ultra-Rare | $758M | $900M-1B | Modest growth, stable |
| Total | $4.2-4.5B | $5.7-6.7B | Lifecycle management |
| Product | Indication | US Exclusivity | EU Exclusivity | Key Risk |
|---|---|---|---|---|
| TEPEZZA | TED | No high-certainty patents | No major expirations | Low near-term biosimilar risk |
| KRYSTEXXA | Chronic refractory gout | 2030-2036 | Not disclosed | Moderate biosimilar risk post-2030 |
| UPLIZNA | NMOSD, IgG4-RD, gMG | March 7, 2030 | Sept 7, 2027 (SPC to 2032) | High biosimilar risk EU 2027-2032; US 2030+ |
| Ultra-Rare | Various | Not disclosed | Not disclosed | Low (ultra-orphan status) |
| Product | Fit Score | Addressable Patients | Net Revenue/Patient | Total Opportunity |
|---|---|---|---|---|
| KRYSTEXXA | 9/10 | 100,000-200,000 | $325,000 | $32.5B-65B (lifetime value) |
| TEPEZZA | 8/10 | 30,000-50,000 | $150,000 | $4.5B-7.5B (lifetime value) |
| UPLIZNA | 7/10 | 17,000-32,000 | $77,000 | $1.3B-2.5B (lifetime value) |
| Ultra-Rare | 3-4/10 | <5,000 | High | <$100M |
Chronic refractory gout affects over 200,000 Americans, yet diagnostic delays of 1-5+ years are common as patients cycle through oral therapies before being identified as refractory, and current KRYSTEXXA penetration is only ~3,700 patients—less than 2% of eligible patients. With net revenue of $325,000 per patient annually and proven efficacy in reducing flares and tophi when co-administered with methotrexate, Ada Patient Finder can identify undiagnosed CRG patients presenting with recurrent gout flares despite allopurinol/febuxostat treatment, visible tophi, or chronic joint pain—especially those with CKD comorbidities—and navigate them to rheumatology or nephrology for KRYSTEXXA evaluation, capturing a 100,000-200,000 patient opportunity currently lost to treatment inertia and suboptimal oral therapy management.
Thyroid eye disease affects an estimated 100,000 Americans with moderate-to-severe active disease, yet diagnostic delays of 6-18 months are common for atypical presentations, and up to 20-30% of cases may be underdiagnosed when lower lid retraction and subtle signs are missed. With TEPEZZA generating $150,000+ in net revenue per patient and a proven track record of reducing proptosis and improving quality of life, Ada Patient Finder's multi-symptom assessment can identify undiagnosed TED patients presenting with bulging eyes, double vision, or eye pain—especially those with Graves' disease history—and navigate them to ophthalmology or endocrinology specialists for timely treatment, capturing a 30,000-50,000 patient opportunity currently lost to delayed diagnosis or watchful waiting.
Neuromyelitis optica spectrum disorder (NMOSD) affects approximately 22,000 Americans, with diagnostic delays ranging from 1-4 months to over 5 years as patients are misdiagnosed with multiple sclerosis or other neurological conditions, leading to irreversible vision loss or paralysis. With UPLIZNA generating $77,000 in net annual revenue per patient and proven efficacy in preventing relapses in AQP4-antibody positive patients, Ada Patient Finder can identify undiagnosed NMOSD patients presenting with sudden vision loss, severe limb weakness, intractable nausea/vomiting, or transverse myelitis—especially those with autoimmune comorbidities or Asian/Black ethnicity—and navigate them to neurology for urgent AQP4-IgG testing and UPLIZNA evaluation. Beyond NMOSD, UPLIZNA's recent IgG4-related disease approval and pending generalized myasthenia gravis filing expand the addressable market to an additional 10,000-20,000 patients.
Additional sources 51-99 available in full markdown report. Total 99 unique references cited.